Amorfrutins Are Natural PPARgamma Agonists with Potent Anti-inflammatory 
Properties

Fuhr, Luise; Rousseau, Morten; Plauth, Annabell; Schroeder, Frank C.; Sauer, Sascha

doi:10.1021/np500747y

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Amorfrutins Are Natural PPARgamma Agonists with Potent Anti-inflammatory Properties

MPS-Authors

Fuhr, Luise
Independent Junior Research Groups (OWL), Max Planck Institute for Molecular Genetics, Max Planck Society;

Rousseau, Morten
Independent Junior Research Groups (OWL), Max Planck Institute for Molecular Genetics, Max Planck Society;

Plauth, Annabell
Independent Junior Research Groups (OWL), Max Planck Institute for Molecular Genetics, Max Planck Society;

/persons/resource/persons50512

Sauer, Sascha
Nutrigenomics and Gene Regulation (Sascha Sauer), Independent Junior Research Groups (OWL), Max Planck Institute for Molecular Genetics, Max Planck Society;

External Resource

http://www.ncbi.nlm.nih.gov/pubmed/25938459
(Any fulltext)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

Fuhr.pdf
(Publisher version), 2MB

Supplementary Material (public)

There is no public supplementary material available

Citation

Fuhr, L., Rousseau, M., Plauth, A., Schroeder, F. C., & Sauer, S. (2015). Amorfrutins Are Natural PPARgamma Agonists with Potent Anti-inflammatory Properties. Journal of Natural Products, 78(5), 1160-1164. doi:10.1021/np500747y.

Cite as: https://hdl.handle.net/11858/00-001M-0000-002A-5FE9-1

Abstract

Amorfrutins are isoprenoid-substituted benzoic acid derivatives, which were found in Amorpha fruticosa L. (bastard indigo) and in Glycyrrhiza foetida Desf. (licorice). Recently, amorfrutins were shown to be selective activators of the nuclear receptor PPARgamma. Here, we investigated the effects and PPARgamma-based mechanisms of reducing inflammation in colon cells by treatment with amorfrutins. In TNF-alpha-stimulated colon cells amorfrutin A (1) reduced significantly the expression and secretion of several inflammation mediators, in part due to interaction with PPARgamma. These results support the hypothesis that amorfrutins may have the potential to treat inflammation disorders such as chronic inflammatory bowel diseases.